Managed Account Advisors’s Celldex Therapeutics CLDX Stock Holding History

Managed Account Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$1.69M	Buy	4,461 +601	+16%	+$239K	﹤0.01%	1901
2015 Q1	$1.61M	Buy	3,860 +332	+9%	+$119K	﹤0.01%	1938
2014 Q4	$966K	Buy	3,528 +1,475	+72%	+$367K	﹤0.01%	2070
2014 Q3	$399K	Buy	2,053 +428	+26%	+$93.3K	﹤0.01%	2217
2014 Q2	$398K	Sell	1,625 -1,234	-43%	-$279K	﹤0.01%	2193
2014 Q1	$757K	Sell	2,859 -108	-4%	-$41.4K	﹤0.01%	2021
2013 Q4	$1.08M	Buy	2,967 +1,593	+116%	+$614K	﹤0.01%	1907
2013 Q3	$730K	Buy	+1,374	New	+$471K	﹤0.01%	1938

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Managed Account Advisors's CLDX Position: Q2 2015 in Review

Managed Account Advisors increased its Celldex Therapeutics (CLDX) stake by 16% in Q2 2015, buying an estimated $239K and bringing the position to 4,461 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1901.

Managed Account Advisors first reported a position in CLDX in Q3 2013 and has held it in 8 quarters since. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

Managed Account Advisors held 4,461 shares of Celldex Therapeutics worth $1.69M as of Q2 2015.
Managed Account Advisors bought 601 Celldex Therapeutics shares in Q2 2015, an estimated $239K.
Celldex Therapeutics made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1901 holding.
Managed Account Advisors first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 8 quarters since.
186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.